Marshall Wace, LLP Immunic, Inc. Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Immunic, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 563,543 shares of IMUX stock, worth $524,094. This represents 0.0% of its overall portfolio holdings.

Number of Shares

563,543

Previous 417,883 34.86%

Holding current value

$524,094

Previous $417,000 47.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.94 - $1.3 $136,920 - $189,358	145,660 Added 34.86%	563,543 $614,000
Q4 2024 Feb 13, 2025	SELL	$1.0 - $1.61 $48,404 - $77,930	-48,404 Reduced 10.38%	417,883 $417,000
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.95 $460,799 - $831,998	426,666 Added 1076.87%	466,287 $769,000
Q2 2024 Aug 14, 2024	SELL	$0.98 - $1.44 $9,709 - $14,267	-9,908 Reduced 20.0%	39,621 $43,000
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $34,485 - $46,282	30,250 Added 156.91%	49,529 $65,000
Q4 2023 Feb 14, 2024	SELL	$0.97 - $1.6 $166,427 - $274,520	-171,575 Reduced 89.9%	19,279 $28,000
Q3 2023 Nov 14, 2023	BUY	$1.35 - $2.87 $257,652 - $547,750	190,854 New	190,854 $280,000
Q1 2023 May 15, 2023	BUY	$1.35 - $2.87 $49,913 - $106,112	36,973 Added 37.93%	134,459 $200,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $82,617 - $789,620	73,113 Added 299.98%	97,486 $136,000
Q3 2022 Nov 14, 2022	BUY	$3.0 - $5.49 $73,119 - $133,807	24,373 New	24,373 $77,000
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $23,201 - $34,680	-2,432 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $17,850 - $24,928	2,432 New	2,432 $24,000

Others Institutions Holding IMUX

# of Institutions

Shares Held

47M

Call Options Held

1.14M

Put Options Held

130K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $28.4M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Immunic, Inc. Transaction History